Cladribine Tablets Reduce Brain Atrophy in MS

                                                                  

EMD Serono has recently published Phase 3 clinical data showing that Cladribine tablets reduced the annualized rate of brain volume loss (BVL, brain atrophy) compared to placebo in patients with relapsing-remitting multiple sclerosis (RRMS).

The study, “Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets,” which appeared in the Multiple Sclerosis Journal, reports the results of a post hoc analysis of the Phase 3 CLARITY study.

CLARITY was a randomized, double-blind, three-arm, placebo-controlled, multi-center Phase 3 clinical trial (NCT00213135) that evaluated the safety and efficacy of oral Cladribine in 1,326 RRMS patients. The primary endpoint was the assessment of the annualized rate of relapse (ARR) at 96 weeks, and key secondary endpoints included the number of relapse-free patients and the sustained progression of disability.

Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews